Who We Help: DiviTum TKa is a new FDA cleared blood test that monitors cancer
Oncologists, Pharma, Biotech and others who work in clinical trials use the DiviTum test to monitor disease progression.

Biovica International's DiviTum TKa is a blood test measuring tumor cell proliferation to monitor disease progression in solid tumors.
biovica.comCrawled Nov 17, 2026
Oncologists, Pharma, Biotech and others who work in clinical trials use the DiviTum test to monitor disease progression.
These results are highly encouraging and highlight the potential of DiviTum TKa test to evaluate treatment efficacy
Biovica initiates a clinical trial to study DiviTum TKa levels and medication dose effects in metastatic breast cancer patients in collaboration with Yale.
Biovica partners with IT Health Fusion to commercialize the DiviTum TKa assay in Italy, where 17,000 women are diagnosed with metastatic breast cancer annually.
Biovica partners with IT Health Fusion to commercialize DiviTum TKa in Italy, where 17,000 women annually receive a metastatic breast cancer diagnosis.
Biovica secures a second work order under its expanded Master Services Agreement with a leading pharmaceutical company for a new oncology program.
Biovica seeks driven individuals to join its growing team.
Amy has a PhD in Pathology from Boston University School of Medicine and a BS in Biochemistry from the University of New Hampshire.
Biovica’s Board of Directors consists of six ordinary members elected by the AGM, including Chairman of the Board.
Henrik has 20+ years of experience in the in vitro diagnostic (IVD) industry bringing biomarker assays into global clinical use and managing roles within R&D and Business Development.
Mattias has over 25 years of experience in pharma and biotech, focusing on oncology drug development and biomarker innovation.
Biovica, a Swedish biotech company, develops & commercializes novel blood-based biomarker assays. DiviTum measures cell proliferation.
Biovica holds FDA 510(k) clearance, CE marking, and ISO 13485:2016 certification.
DiviTum TKa test is a blood test that measures cell proliferation and is used as an aid in monitoring cancer progression
Biovica secures a second work order from a top global pharmaceutical firm under its expanded Master Services Agreement. The order covers a new oncology program, building on the first work order valued at approximately **$100,000**, announced in July 2026. The company specializes in blood-based cancer monitoring solutions.
Biovica International’s board approves a rights issue allowing issuance of up to **97,303,733 shares**, as confirmed by an extra general meeting. The resolution follows a formal board decision on **September 9, 2026**. Shareholders now determine the final allocation under the approved framework.
Biovica secures its first work order under a new master services agreement, valued at approximately **$85,000**, for **DiviTum® TKa testing** in a **Phase 1 oncology study**. The study evaluates an **oral next-generation CDK inhibitor** in patients with **advanced solid tumors**, marking its first-in-human trial. The agreement supports Biovica’s role in clinical testing for emerging cancer therapies.
Biovica consolidates evidence for its **DiviTum TKa assay** through a meta-analysis of 15 studies covering nearly 3,000 women with hormone receptor-positive metastatic breast cancer. All studies used the same tool to measure tumor proliferation, strengthening the assay’s clinical validation.
Biovica, a blood-based cancer monitoring company, secures a **Master Services Agreement (MSA)** with a U.S. biotech subsidiary focused on next-generation precision cancer therapies. The deal expands Biovica’s pharma services offerings, though specific terms or projects remain undisclosed. The partnership aligns Biovica’s liquid biopsy expertise with the subsidiary’s drug development pipeline.
Biovica expands its partnership with a leading global pharmaceutical company to support next-generation oncology programs. The agreement extends Biovica’s **DiviTum® TKa** blood-based cancer monitoring services for the company’s oncology development pipeline. This collaboration leverages Biovica’s specialized testing to advance liquid biopsy-based solutions in cancer research.
Biovica secures a Japanese patent for its **TKa** technology in **immune checkpoint inhibitor** treatments, enabling blood-based cancer monitoring. The patent covers applications in tracking cancer progression and therapy response for patients undergoing immunotherapy. Biovica specializes in liquid biopsy solutions for oncology.
Biovica’s **DiviTum TKa** demonstrates early detection of treatment-specific biological responses in **HR+/HER2- metastatic breast cancer**, according to new Phase III PEARL study data published in the *European Journal of Cancer*. The findings highlight treatment-dependent dynamics that distinguish it from standard biomarkers, reinforcing its potential clinical utility.